116 related articles for article (PubMed ID: 12442056)
1. [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].
Perrier L; Sebban C; Philip I; Standaert B; Morelle M; Latour JF; Biron P; Philip T
Rev Epidemiol Sante Publique; 2002 Sep; 50(4):393-403. PubMed ID: 12442056
[TBL] [Abstract][Full Text] [Related]
2. CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.
Baron F; Copizza S; Baudoux E; Jerusalem G; Fillet G; Beguin Y
Haematologica; 2004 Sep; 89(9):1146-8. PubMed ID: 15377481
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
4. Health care costs for treatment of disseminated breast cancer.
Dahlberg L; Lundkvist J; Lindman H
Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
[TBL] [Abstract][Full Text] [Related]
5. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
7. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
De Rosa L; Lalle M; Pandolfi A; Pescador L
Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
9. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
10. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
[TBL] [Abstract][Full Text] [Related]
11. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
[TBL] [Abstract][Full Text] [Related]
12. [Cost analysis of the treatment of Hodgkin's disease].
Charlińiski G; Wiktor-Jedrzejczak W
Wiad Lek; 2006; 59(3-4):164-9. PubMed ID: 16813258
[TBL] [Abstract][Full Text] [Related]
13. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
Sorá F; Piccirillo N; Chiusolo P; Laurenti L; Marra R; Bartolozzi F; Leone G; Sica S
Cancer; 2006 Feb; 106(4):859-66. PubMed ID: 16419074
[TBL] [Abstract][Full Text] [Related]
15. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study.
Mishra V; Andresen S; Brinch L; Kvaløy S; Ernst P; Lønset MK; Tangen JM; Wikelund J; Flatum C; Baggerød E; Helle B; Vaaler S; Hagen TP
Bone Marrow Transplant; 2005 Jun; 35(12):1149-53. PubMed ID: 15880133
[TBL] [Abstract][Full Text] [Related]
16. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.
Freeman M; Vose J; Bennett C; Anderson J; Kessinger A; Turner K; Pierson J; Bishop M; Bierman P; Armitage J
Bone Marrow Transplant; 1999 Sep; 24(6):679-84. PubMed ID: 10490736
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
18. Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ; Scuffham PA; McCollam PL; Newby DE
Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731
[TBL] [Abstract][Full Text] [Related]
19. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
20. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Bishton MJ; Lush RJ; Byrne JL; Russell NH; Shaw BE; Haynes AP
Br J Haematol; 2007 Mar; 136(5):752-61. PubMed ID: 17313378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
